Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

FTH Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Faeth Therapeutics, Inc.NASDAQ: FTH

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue remains negative

Q2 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was -$4.85M.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$1.21M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
-$4.85M— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Revenue vs competitors

How FTH compares with its peers on the latest reported figures

  • FTH's LTM Jun 2026 revenue of -$4.85M is the lowest of the 10 companies compared; the peer median is $21.61M.
FTH Competitors Peer median
Revenue for FTH and competitors
Company Period LTM YoY 3-year CAGR
PBYIPuma Biotechnology, Inc.LTM Mar 2026$227.18M -2.4%+0.0%
NUVBNuvation Bio Inc.LTM Jun 2026$169.9M +1083.6%—
KURAKura Oncology, Inc.LTM Mar 2026$71.64M +5.4%—
VSTMVerastem, Inc.LTM Mar 2026$49.59M +395.8%+128.4%
JANXJanux Therapeutics, Inc.LTM Mar 2026$21.61M +131.5%+5.1%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.72M +138.9%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$10.35M +23.9%+123.2%
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 -100.0%+35.9%
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ——
FTHFaeth Therapeutics, Inc.LTM Jun 2026-$4.85M ——
Peer median (excluding FTH) $21.61M+77.7%+35.9%

Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue685K1.81M571K551K0
Gross Profit(685K)(1.81M)(571K)(551K)0
Gross Margin—————
Research & Development21.66M29.58M18.3M18.63M10.96M
Selling, General & Admin15.14M17.73M18.77M12.49M11.33M
Operating Expenses36.8M47.31M36.49M31.11M22.29M
Depreciation & Amortization685K1.81M3.68M551K139K
EBITDA(35.44M)(46.56M)(33.39M)(29.52M)(20.91M)
EBITDA Margin—————
Operating Income(37.48M)(49.12M)(37.06M)(31.66M)(22.29M)
Operating Margin—————
Interest Income800K1.78M3.62M2.55M1.24M
Interest Expense670K219K144K90K32K
Other Income / Expenses688K532K2.96M1.51M1.2M
Income Before Tax(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Net Margin—————
EPS (Basic)(26.56)(31.65)(24.40)(24.01)(16.72)
EPS (Diluted)(26.56)(31.65)(24.40)(24.01)(16.72)
Weighted Avg Shares1.39M1.54M1.4M1.26M1.26M
Weighted Avg Shares (Diluted)1.39M1.54M1.4M1.26M1.26M

Faeth Therapeutics, Inc.

NASDAQ:FTH

Intrinsic Alpha fair value

Locked

Current Price

$8.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.